Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous tanezumab for hip or knee osteoarthritis pain
2013-004508-21Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in knee osteoarthritis (OA) and hip osteoarthritis (3 arms), sponsored by Pfizer. Primary endpoint: Co-primary efficacy endpoints at Week 24. Started Dec 2015; status: completed.
02
Drugs
tanezumab
03
Conditions
knee osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on 2013-004508-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004508-21.